Xinsorb® Bioresorbable Sirolimus-eluting Scaffold

Completely degradable and resorbable

The final degradation products of the stent are water and carbon dioxide, reducing the risk of late thrombosis.
Easy to re-stent even after target lesion restenosis.
Completely degradable and resorbable, reducing the risk of foreign body reaction.
Help to restore and improve the physiological function of the diseased vessels.
Compatible with MRI & CT

Patients with myocardial ischemia or angina pectoris caused by coronary artery stenosis or occlusion.
Patients with primary or in-situ coronary thrombosis.
The diameter of the diseased vessel is between 2.75mm-3.75mm, and the length of the diseased vessel is ≤24mm
Patients with probable severe acute occlusion complications after PTCA.
Patients with obvious residual stenosis in the lesion after PTCA.

35-year-old man with type II diabetes and subacute myocardial infarction.

5th Sep. 2013

Before

After the surgery (3.0*18mm XINSORB®)

6 months and 2 years after the surgery

6 months and 2 years after the surgery

Clinical data: The comparison of single-group target value test evaluation indicators results in 2 years

Analysis of 3-year clinical follow-up data

The XINSORB® Bioresorbable Sirolimus-eluting Scaffold (hereinafter referred to as XINSORB® Scaffold System) is composed of a balloon-expandable absorbable coronary stent, a drug coating and a delivery system. As shown in the figure.